OR WAIT null SECS
© 2023 MJH Life Sciences and Applied Clinical Trials Online. All rights reserved.
© 2023 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
February 03, 2023
Craig Coleman, PharmD, Professor at the University of Connecticut, and the Observational Study in Cancer-Associated Thrombosis for Rivaroxaban (OSCAR) study's principal investigator discusses the ins and outs of the study.
January 24, 2023
Webinar Date/Time: Mon, Feb 13, 2023 10:00 AM EST
November 18, 2022
Webinar Date/Time: Tuesday, December 13, 2022 at 10am ET | 3pm GMT | 4pm CET
August 03, 2022
Survey among readers evaluates the trajectory of RWD and how it can be more widely adopted.
June 03, 2022
Addressing sources of tension on differentiating types of data.
May 02, 2022
By integrating real-world data more deeply into the process of clinical research, life sciences stakeholders can open up new possibilities for therapeutic development and the evidence-based treatment of hematologic cancers.
July 08, 2021
RWE can augment, extend, or enrich the findings from clinical trials to provide valuable evidence to support the development programs for product approvals.
June 14, 2019
C.K. Wang, MD, senior medical director at COTA Inc., discusses the impact of RWD and RWE in clinical oncology.
April 01, 2019
A look at the scope of the agency’s draft framework for evaluating the use of RWE to support new drug approvals and the implications for sponsors.
With outcomes from “real life” a critical compliment to clinical trial data, the importance of involving an epidemiologist at study inception is explored.